INTRODUCTION
Triple-negative breast cancer (TNBC), a subtype of breast cancer that is negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), comprises 15-20% of breast cancers. Compared to other types of breast cancer, TNBC is more aggressive and has a worse prognosis because of its tendency to metastasize and recur. 1 The major cause of death of patients with TNBC is recurrence (30-40% of cases), which might be due to the cancer stem-like cell (CSC) phenotype of TNBC cells. 2, 3 CSCs, a subpopulation of cancer cells, possess the capacity to self-renew and give rise to heterogeneous lineages that make up a tumor. 4, 5 CSCs play a critical role in tumor initiation, recurrence and metastasis and are responsible for resistance to chemotherapy and radiotherapy. [5] [6] [7] [8] c-Jun N-terminal kinase (JNK) has been reported to promote CSC self-renewal in glioma by enhancing expression of genes important for CSC self-renewal and maintenance. 9 JNK is a member of the MAPK family, which also includes ERK and p38 MAPKs. Three major JNK isoforms, JNK1, JNK2 and JNK3, have been identified. JNK1 and JNK2 are ubiquitously expressed, whereas JNK3 is expressed predominantly in the brain, heart and testis. 10 JNK is activated through phosphorylation on Thr183 and Tyr185 residues by MAPK kinase MKK4/JNKK1 or MKK7/JNKK2. 11 Once activated, JNK phosphorylates a large range of substrates, including transcription factors, such as c-Jun, activating transcription factor-2 (ATF-2), Elk-1, p53 and c-Myc, and other molecules. 11 JNK mediates many cellular events via activating c-Jun through phosphorylation on Ser63 or Ser73 residues. JNK has been implicated in proliferation, differentiation, apoptosis, stress response and inflammation. JNK also plays a vital role in malignant transformation and metastasis in different cancers. 12, 13 JNK is highly activated in basal-like TNBC. 14 Reduced JNK activation is associated with better overall survival of patients with infiltrating ductal breast carcinoma. 15 However, the roles of JNK in regulating CSC phenotype and tumorigenesis in TNBC remain unknown.
In this study, we investigated the role of JNK signaling in regulating CSCs and tumorigenesis in TNBC. We found that JNK regulates TNBC tumorigenesis by promoting CSC self-renewal and maintenance through Notch1 signaling via activation of c-Jun. We also found that inhibition of JNK signaling by JNK-IN-8, an adenosine triphosphate-competitive irreversible pan-inhibitor of JNK that targets JNK1, JNK2 and JNK3 by binding to the cysteine 116 (Cys116) residue, 16 suppressed tumor growth in a TNBC xenograft mouse model by inhibiting acquisition of the CSC phenotype. Our findings indicate that the JNK signaling pathway is a potential therapeutic target for eliminating CSCs in TNBC.
RESULTS High c-Jun mRNA level is associated with shorter disease-free survival (DFS) of patients with TNBC, and c-Jun activation correlates with JNK activation c-Jun, a transcription factor and a substrate of JNK, ERK and p38, has been implicated in progression of different cancers. [17] [18] [19] However, there has been no systematic analysis of association between expression and activation of c-Jun and clinical outcomes of patients with TNBC. We first compared protein expression levels of total c-Jun and phosphorylated c-Jun (pc-Jun) in primary tumors of patients with TNBC and non-TNBC using a public reverse-phase protein array (RPPA) data set of The University of Texas MD Anderson Cancer Center. 20 The expression level of total c-Jun was significantly higher in tumors of patients with TNBC than in tumors of patients with non-TNBC (P o 2.2e-16; Figure 1a , left panel). The expression level of c-Jun phosphorylated at Ser73 was also higher in tumors of patients with TNBC than in tumors of patients with non-TNBC; however, the difference was not significant (P = 0.063; Figure 1a , right panel). Furthermore, the expression level of total c-Jun was significantly higher in tumors of patients with TNBC than in tumors of patients with estrogen receptor-negative and HER2-positive (HER2+) breast cancer (P = 0.003; Supplementary Figure 1a Figure 1a, right panel) ; however, no difference was observed between tumors of patients with TNBC and tumors of patients with HER2+ breast cancer (P = 0.787; Supplementary Figure 1a , right panel). We next examined the association between mRNA level of c-Jun and DFS of patients with primary TNBC using combined data from data sets previously published by Wang et al 21 and Schmidt et al. 22 We found that high mRNA level of c-Jun correlated with shorter DFS of patients with primary TNBC (P = 0.025; Figure 1b) . These results suggested that c-Jun may have clinical significance in TNBC.
Since c-Jun is a substrate of JNK, ERK and p38, we next examined the association between activation of JNK or p38 and activation of c-Jun in primary tumors of patients with TNBC using the RPPA data set. The association between ERK activation and c-Jun activation could not be examined because no data on ERK level were available. We found that expression level of c-Jun phosphorylated at Ser73 correlated with expression level of JNK phosphorylated at Thr183 (r Pearson = 0.645; P o 2.2e-16; Figure 1c) but not with expression level of phospho-p38 (r Pearson = − 0.086; P = 0.334; data not shown). Similar results were observed in all TNBC tumors, including primary and metastatic tumors (data not shown).
On the basis of the association of higher c-Jun mRNA level with reduced DFS and the correlation of c-Jun activation with JNK activation, we hypothesized that JNK/c-Jun signaling contributes to TNBC tumorigenesis.
Inhibition of JNK activity suppresses c-Jun phosphorylation and thereby inhibits cell growth We first examined the role of JNK/c-Jun signaling in TNBC cell growth. We used HCC70, SUM149 and MDA-MB-231 TNBC cell lines, which express high levels of JNK and are tumorigenic and invasive. Because of limited expression of JNK3 in tissues, 10 we focused on JNK1 and JNK2. We found that inhibition of JNK activity using JNK-IN-8 in HCC70, SUM149 and MDA-MB-231 cells specifically suppressed c-Jun phosphorylation at both Ser63 and Ser73 but did not suppress phosphorylation of ATF-2 at Thr71 or Elk-1 at Ser383 (Figure 1d; Supplementary Figure 1b JNK signaling is required for CSC self-renewal and maintenance JNK has been shown to promote self-renewal and maintenance of CSCs in glioma, 23 and high JNK expression is seen in CSCs isolated from patient glioma cells. 24 In hepatoma, high JNK1 activation is associated with overexpression of stem cell markers. 13 However, whether JNK regulates CSCs in TNBC remains unknown. To address this knowledge gap, we knocked down JNK and assessed the effects on CSC self-renewal and maintenance using the mammosphere formation assay, a standard assay to study stem cell properties in vitro. 25 Compared to the SCR control, JNK1 or JNK2 knockdown significantly reduced mammosphere formation in both HCC70 and SUM149 cells, with JNK2 knockdown having a greater effect (Figure 3a Figure 5e) , confirming that JNK-IN-8 inhibits mammosphere formation by specifically targeting JNK. In contrast, compared to overexpression of the vector control or dominant-negative JNK (apf, a JNK mutant in which the dual phosphorylation motif Thr183-Pro-Tyr185 was replaced with Ala-Pro-Phe), overexpression of constitutively active MKK7-JNK1 or MKK7-JNK2 led to an increase in mammosphere formation (Supplementary Figure 6) . Unexpectedly, in dominantnegative JNK2-overexpressing cells, an increase in mammosphere formation was observed (Supplementary Figure 6) . This effect may have been due to incomplete inhibition of JNK2 kinase activity, an interpretation supported by the finding of Wojtaszek et al showing that expression of dominant-negative JNK2 in stable clones inhibited hypertonicity-induced JNK activation by 40-70%. 26 Taken together, these results clearly demonstrate that both JNK1 and JNK2 promote CSC self-renewal and maintenance in TNBC, with JNK2 playing a dominant role.
JNK regulates Notch1 transcription via activating c-Jun
To dissect the molecular mechanisms underlying JNK signalingmediated CSC regulation, we treated HCC70 and SUM149 cells with JNK-IN-8 for 48 h and then performed stem cell RT-PCR array analysis. We found that JNK inhibition led to downregulation of stem cell-related molecules Notch1, FGF2 and cyclin D1 and upregulation of stem cell-related molecules FZD1, FRAT1, HDAC1 and BMP3 at the mRNA level (Supplementary Table 2 ). Furthermore, Western blot analysis showed that of these molecules, Notch1 was the one whose expression at the protein level was most reduced following JNK-IN-8 treatment (Figure 4a ), suggesting the involvement of Notch1 in JNK signaling-mediated CSC regulation. Next, we assessed whether JNK regulates Notch1 expression by examining the effects of JNK knockdown on Notch1 expression. We observed a reduction in Notch1 expression at the protein level following JNK1 or JNK2 knockdown in both HCC70 and SUM149 cells, with JNK2 knockdown having a greater effect (Figure 4b ). The inhibitory effect of JNK knockdown on Notch1 expression was confirmed using the second set of siJNK1 and siJNK2 (Supplementary Figure 1b, right panel) . As expected, a reduction in c-Jun phosphorylation at both Ser63 and Ser73 was also observed (Figure 4b; Supplementary Figure 1b 
DISCUSSION
JNK has been implicated in malignant transformation and metastasis in different cancers. 12, 13 However, no studies to date have addressed the roles of JNK in regulating CSCs and tumorigenesis in TNBC. Here, we found that c-Jun was associated with clinical outcomes of TNBC patients and that c-Jun activation correlated with JNK activation in TNBC tumors. We also found that JNK promoted CSC self-renewal and maintenance in TNBC through upregulation of Notch1 via activation of c-Jun. Suppression of JNK signaling inhibited CSC phenotype, leading to growth inhibition of TNBC cells both in vitro and in vivo. Taken together, our findings demonstrate that JNK/c-Jun/Notch1 signaling promotes CSC phenotype, which might contribute to tumor initiation and progression in TNBC (Figure 6d) , and that targeting JNK signaling is a potential therapeutic strategy for TNBC.
JNK was originally discovered as a regulator of apoptosis in response to a variety of stress stimuli. 27 In recent decades, emerging evidence has suggested that JNK also plays a role in proliferation and transformation of different cancers. JNK can potentiate or suppress tumorigenesis depending on the tumor type and the nature of the oncogenic event. We found that suppression of JNK signaling using JNK-IN-8 inhibited cell growth by arresting the cell cycle at G1 or G2/M phase in the case of exposure for short periods or at low doses and by inducing apoptosis in the case of exposure for long periods and at high doses. Furthermore, JNK-IN-8 suppressed tumorigenicity of TNBC cells in a xenograft mouse model. Consistent with our findings, studies by others also support a role for JNK signaling in promoting tumorigenesis, for example, in lymphoma, 28 colorectal cancer 29 and lung cancer. 30 In breast cancer, JNK is highly activated in basal-like TNBC; 14 elevated JNK activation is associated with short survival of patients with infiltrating ductal breast carcinoma. 15 Furthermore, overexpression of a constitutively active JNK enhanced migration and invasion of breast cancer cells. 31 These findings suggest a pathological role for JNK signaling in different cancers. In contrast, Gozdecka et al. showed that deletion of JNK promoted Ras-dependent cellular transformation and liver tumor formation through loss of ATF-2. 32 In our study, suppression of JNK activity slightly inhibited activation of ATF-2 or Elk-1 but dramatically inhibited activation of c-Jun. We also found that JNK promoted cellular transformation through upregulation of Notch1 via activation of c-Jun. These differences between our findings and the findings of Gozdecka et al. might be due to differences in the cell types used (human TNBC cell lines vs Ras-transformed mouse embryonic fibroblasts) and tumor types studied (breast vs liver). Interestingly, our study showed that JNK2 knockdown but not JNK1 knockdown largely suppressed activation of ATF-2, suggesting that JNK2 might promote CSC phenotype in TNBC through both ATF-2 and c-Jun, which form heterodimers and stimulate cAMP-responsive element-dependent transcription. 33 This finding may explain why JNK2 knockdown had more substantial inhibitory effects than JNK1 knockdown on TNBC cellular activities and also suggests that JNK1 and JNK2 may regulate TNBC tumorigenesis through different mechanisms. Studies have shown that JNK1 and JNK2 have redundant but distinct functions. Both JNK1 and JNK2 have been shown to promote cell growth, which is supported by the fact that intact mouse embryos with either jnk1 -/-or jnk2 -/-survive, whereas genetic disruption of both Jnk1 and Jnk2 alleles in mouse embryos is lethal. 34 JNK1, but not JNK2, was essential for tumor necrosis factor α-induced proliferation and differentiation of myoblasts. 35 Skin tumorigenesis was enhanced in jnk1 -/-mice but suppressed in jnk2 -/-mice. 36 Thus, the functions of JNK isoforms depend on the cell type, nature of the stimulus and involvement of other signaling pathways.
Here, we show that JNK/c-Jun signaling regulated transcription of Notch1, which appeared to be responsible for maintaining CSC stemness in TNBC. Aberrantly activated Notch signaling has been implicated in initiation and progression of many different cancers. [37] [38] [39] Notch signaling is well known to regulate breast stem cell self-renewal and cell-fate determination 40, 41 and to be critical for maintaining CSC stemness in glioma. 23 Inhibition of Notch signaling reduced CD133 + CSC subpopulations in vitro and brain tumor formation in vivo.
23 Consistent with our findings, Yoon et al. reported that JNK signaling acted through Notch2 to promote self-renewal of glioma CSCs. 23 Harrison et al. showed that breast CSC activity was governed through Notch4 signaling. 42 More importantly, Notch signaling was aberrantly activated in breast cancer cell lines and invasive primary breast tumor samples. 42 Our study demonstrates that JNK/c-Jun/Notch1 signaling governs self-renewal and maintenance of CSCs in TNBC. In contrast, Cantrell et al. showed that JNK2 inhibited p53/Notch1-dependent cell differentiation in normal and cancerderived mammary cells through downregulation of Notch1 transcription. 43 This inconsistency might be due to differences in the cell types used (human TNBC cell lines vs murine mammary cell lines), tumor types studied (human breast vs murine polyoma middle T antigen mammary) and downstream molecules involved (c-Jun vs p53).
Development of effective therapies for TNBC has been challenging because of the lack of well-defined therapeutic targets. It is believed that many cancers originate from CSCs and that CSCs are responsible for tumor recurrence and metastasis because of their capacity to self-renew and to give rise to heterogeneous lineages that comprise a tumor. 4, 5 The importance of CSCs in tumor initiation and metastasis has positioned CSCs as a potential target for cancer treatment. JNK signaling was essential for self-renewal and maintenance of glioma CSCs, 23 and a high expression level of JNK was seen in CSCs isolated from patient glioma cells. 44 Moreover, elevated JNK1 activation was associated with a poor prognosis in hepatoma and enhanced expression of stem cell markers. 13 JNK is highly activated in basal-like TNBC.
14 These findings along with ours suggest that controlling CSCs through targeting JNK signaling might overcome the problems of metastasis, recurrence and resistance seen with current chemotherapies. Although our in vivo study showed that JNK inhibition reduced CSC phenotype, we recognize that further in vivo studies are needed to confirm that the tumor-initiating capacity of CSCs is dependent on JNKs. An appropriate experiment would be to examine the effects of stable knockdown of JNK1 or JNK2 on the tumor-initiating capacity of CSCs using a limiting-dilution xenotransplantation mouse model. 45, 46 In conclusion, our findings demonstrate that JNK/c-Jun/Notch1 signaling plays an important role in TNBC tumorigenesis via regulating CSC phenotype and indicate that targeting JNK signaling has potential for TNBC treatment.
MATERIALS AND METHODS

Clinical analysis
Expression levels of proteins of interest in tumors were compared between patients with primary TNBC (n = 129), non-TNBC (n = 267), HER2+ breast cancer (n = 19) and HR+ breast cancer (n = 248) using a public RPPA data set of MD Anderson Cancer Center. The association between mRNA levels of proteins and DFS of patients with TNBC (n = 79) was determined using combined data from data sets previously published by Wang et al. 21 and Schmidt et al. 
Mammosphere formation assay
To determine the impact of target gene knockdown on mammosphere formation, at 48 h after siRNA transfection, single-cell suspensions were prepared in TeSR-E8 medium (STEMCELL Technologies Inc., Vancouver, BC, Canada) supplemented with MammoCult proliferation supplements, 1% antibiotic/antimycotic, 4 μg/mL heparin and 0.48 μg/mL hydrocortisone. The cells were then seeded in six-well ultra-low attachment plates (Corning Inc., Corning, NY, USA). To determine the impact of JNK inhibition on mammosphere formation, the cells were cultured with or without JNK-IN-8. After a 7-day incubation, mammospheres greater than 80 μm in diameter were counted using the GelCount system (Oxford Optronix Ltd., Milton Park, Abingdon, UK).
RT-PCR stem array analysis
A human stem cell RT 2 Profiler PCR array (Qiagen Inc., Valencia, CA, USA) was used to evaluate the expression of 84 specific genes. Cells were treated with JNK-IN-8 (2.5 μM) for 48 h, and then total RNA was extracted from the cells using the miRNeasy mini kit (Qiagen Inc.) according to the manufacturer's instructions. cDNA was synthesized using the RT 2 First Strand Kit (Qiagen Inc.) and dispensed into the RT 2 Profiler PCR array. Each PCR array included five housekeeping genes (B2M, HPRT1, RPL13A, GAPDH and ACTB), a control for genomic DNA contamination, a reverse transcription control and a positive PCR control. The data were analyzed using Qiagen software (http://www.sabiosciences.com/pcr/arrayanalysis.php).
The criteria used to define differential expression of genes between each pair of classes tested were P o0.05 and false discovery rateo 0.2.
Quantitative RT-PCR Cells were transfected with SCR (Sigma-Aldrich, St Louis, MO, USA) or siRNA targeting c-Jun (Sigma-Aldrich). Seventy-two or 96 h later, total RNA was extracted from the cells using the miRNeasy mini kit (Sigma-Aldrich) according to the manufacturer's instructions. One-step quantitative PCR reactions were performed using the SYBR green qPCR kit (Bio-Rad Laboratories, Hercules, CA, USA) with a pair of Notch1 primers (5′-ACAGCCTCAACGGGTACAA-3′ (forward) and 5′-CACACGTAGCCACTGGT CAT-3′ (reverse)) and a pair of human β-Actin primers (5′-GCGGGAAAT CGTGCGTGACATT-3′ (forward) and 5′-AGACAGTCTCCACTCACCCAGGAAG-3′ (reverse)). The mRNA of human housekeeping gene β-Actin was used as a normalization control. The mRNA levels of Notch1 were first normalized to the mRNA levels of β-Actin, and then the fold induction of Notch1 mRNA was calculated on the basis of the Notch1 mRNA level in SCR-treated control cells.
Luciferase reporter assay
Cells were transfected with SCR or siRNA targeting c-Jun (Sigma-Aldrich) and then transfected 48 h later with HRPM22069-PG04 and NEG-PG04 expression vectors (Genecopoeia, Rockville, MD, USA). The HRPM22069-PG04 vector contains the Notch1 promoter and the coding sequences for both Gaussia luciferase and secreted alkaline phosphatase. The NEG-PG04 vector was used as a negative control. At 48 h after transfection, the Gaussia luciferase and secreted alkaline phosphatase signals were measured using the Secrete-Pair dual luminescence assay kit (Genecopoeia) according to the manufacturer's instructions. To control for offtarget effects of the expression plasmids or the transfection procedure, the Gaussia luciferase signal was normalized to that of secreted alkaline phosphatase. 
TNBC xenograft mouse model
Statistics
All the data were presented as mean ± standard deviation except for the RPPA data, for which box-and-whisker plots were used to show the data structure. Differences in the expression levels of proteins between two groups were analyzed using two-tailed Student's t test, and differences among multiple groups were analyzed using one-way analysis of variance. Tukey HSD tests were used for post hoc pairwise analysis. Association between expression levels of proteins was analyzed by Pearson correlation coefficient test. Correlation between mRNA levels of proteins and DFS of patients with TNBC was analyzed by the Kaplan-Meier method. Statistical significance of the in vitro results was assessed by two-tailed Student's t test. Po0.05 was considered significant.
